Table of Contents Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value GLYC The Nasdaq Stock Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumorsWALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are ...

NEW YORK, Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (State or ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Naureen Quibria - Capital One Securities Edward White - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Investor and Analyst [indiscernible] Please note this event is being recorded. Today's remarks will be followed by a que ...

Exhibit 99.2 ...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Bruce Johnson - Chief Commercial Officer Brian Hahn - CFO Conference Call Participants Tara Bancroft - TD Cowen Naureen Quibria - Capital One Securities Edward White - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this tim ...

EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 ROCKVILLE, Md.--(BUSINESS WIRE) – March 27, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million. "With t ...